Evolus, Inc. (NASDAQ:EOLS) Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC trimmed its stake in Evolus, Inc. (NASDAQ:EOLS) by 7.1% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 108,231 shares of the company’s stock after selling 8,301 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.17% of Evolus worth $1,753,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Quest Partners LLC acquired a new position in Evolus in the 2nd quarter valued at $43,000. Quarry LP purchased a new stake in shares of Evolus in the second quarter valued at $54,000. Profund Advisors LLC acquired a new position in Evolus in the second quarter valued at $130,000. Arizona State Retirement System lifted its position in Evolus by 9.4% during the second quarter. Arizona State Retirement System now owns 14,603 shares of the company’s stock worth $158,000 after buying an additional 1,253 shares during the period. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in Evolus in the 3rd quarter worth about $191,000. 90.69% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. Needham & Company LLC reiterated a “buy” rating and set a $22.00 price objective on shares of Evolus in a report on Friday, September 13th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Evolus in a research note on Monday, September 16th. Barclays lifted their price target on shares of Evolus from $16.00 to $20.00 and gave the company an “overweight” rating in a report on Friday, September 13th. Finally, HC Wainwright restated a “buy” rating and set a $27.00 price objective on shares of Evolus in a report on Thursday, November 7th.

Evolus Price Performance

Shares of NASDAQ:EOLS opened at $11.51 on Tuesday. The stock has a 50-day simple moving average of $14.38 and a 200-day simple moving average of $13.84. The stock has a market capitalization of $728.82 million, a P/E ratio of -12.65 and a beta of 1.27. Evolus, Inc. has a 1 year low of $9.65 and a 1 year high of $17.82. The company has a debt-to-equity ratio of 20.58, a quick ratio of 2.23 and a current ratio of 2.47.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.